These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 30345836)

  • 21. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
    Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
    Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Zoning of mucosal phenotype, dysplasia, and telomerase activity measured by telomerase repeat assay protocol in Barrett's esophagus.
    Going JJ; Fletcher-Monaghan AJ; Neilson L; Wisman BA; van der Zee A; Stuart RC; Keith WN
    Neoplasia; 2004; 6(1):85-92. PubMed ID: 15068673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Barrett's Esophagus and esophageal adenocarcinoma.
    Bresalier RS
    Annu Rev Med; 2009; 60():221-31. PubMed ID: 18783330
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Incidence and physiopathology of high-grade dysplasia in Barrett's esophagus].
    Coriat R; Perkins G; Brezault C
    Presse Med; 2011 May; 40(5):496-501. PubMed ID: 21435817
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.
    Lord RV; Brabender J; Wickramasinghe K; DeMeester SR; Holscher A; Schneider PM; Danenberg PV; DeMeester TR
    Surgery; 2005 Nov; 138(5):924-31. PubMed ID: 16291394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma.
    Derks S; Nason KS; Liao X; Stachler MD; Liu KX; Liu JB; Sicinska E; Goldberg MS; Freeman GJ; Rodig SJ; Davison JM; Bass AJ
    Cancer Immunol Res; 2015 Oct; 3(10):1123-1129. PubMed ID: 26081225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry.
    Ramel S; Reid BJ; Sanchez CA; Blount PL; Levine DS; Neshat K; Haggitt RC; Dean PJ; Thor K; Rabinovitch PS
    Gastroenterology; 1992 Apr; 102(4 Pt 1):1220-8. PubMed ID: 1551529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of Mitochondrial Markers in Improved Detection and Risk-Stratification in Barrett's Esophagus Patients.
    Grewal US; Randhawa MS; Mehta A
    Yale J Biol Med; 2019 Sep; 92(3):533-539. PubMed ID: 31543714
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retinoic acid receptor-alpha messenger RNA expression is increased and retinoic acid receptor-gamma expression is decreased in Barrett's intestinal metaplasia, dysplasia, adenocarcinoma sequence.
    Lord RV; Tsai PI; Danenberg KD; Peters JH; Demeester TR; Tsao-Wei DD; Groshen S; Salonga D; Park JM; Crookes PF; Kiyabu M; Chandrasoma P; Danenberg PV
    Surgery; 2001 Mar; 129(3):267-76. PubMed ID: 11231454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What's new in columnar lined esophagus (Barrett's metaplasia)?
    Tadiparthi R; Bansal A; Sharma P
    Curr Opin Gastroenterol; 2008 Jul; 24(4):516-20. PubMed ID: 18622169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Screening for adenocarcinoma in Barrett's esophagus: yes or no, when and how?].
    Sostres C; Lacarta P; Lanas A
    Gastroenterol Hepatol; 2013 Oct; 36(8):520-6. PubMed ID: 23453559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus.
    Zou H; Molina JR; Harrington JJ; Osborn NK; Klatt KK; Romero Y; Burgart LJ; Ahlquist DA
    Int J Cancer; 2005 Sep; 116(4):584-91. PubMed ID: 15825175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biomarkers in Barrett's esophagus (review).
    van Lieshout EM; Jansen JB; Peters WH
    Int J Oncol; 1998 Oct; 13(4):855-64. PubMed ID: 9735417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in mitochondrial stability during the progression of the Barrett's esophagus disease sequence.
    O'Farrell NJ; Feighery R; Picardo SL; Lynam-Lennon N; Biniecka M; McGarrigle SA; Phelan JJ; MacCarthy F; O'Toole D; Fox EJ; Ravi N; Reynolds JV; O'Sullivan J
    BMC Cancer; 2016 Jul; 16():497. PubMed ID: 27431913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus.
    Whitson MJ; Falk GW
    Gastroenterol Clin North Am; 2015 Jun; 44(2):299-315. PubMed ID: 26021196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of Barrett's esophagus with high-grade dysplasia.
    McAllaster JD; Buckles D; Al-Kasspooles M
    Expert Rev Anticancer Ther; 2009 Mar; 9(3):303-16. PubMed ID: 19275509
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cdx1 and c-Myc foster the initiation of transdifferentiation of the normal esophageal squamous epithelium toward Barrett's esophagus.
    Stairs DB; Nakagawa H; Klein-Szanto A; Mitchell SD; Silberg DG; Tobias JW; Lynch JP; Rustgi AK
    PLoS One; 2008; 3(10):e3534. PubMed ID: 18953412
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Screening for Barrett's esophagus.
    Zakko L; Lutzke L; Wang KK
    Minerva Med; 2017 Feb; 108(1):28-42. PubMed ID: 27792223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The relationship between columnar epithelial dysplasia and invasive adenocarcinoma arising in Barrett's esophagus.
    Hamilton SR; Smith RR
    Am J Clin Pathol; 1987 Mar; 87(3):301-12. PubMed ID: 3825997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Barrett's Esophagus: A Comprehensive and Contemporary Review for Pathologists.
    Naini BV; Souza RF; Odze RD
    Am J Surg Pathol; 2016 May; 40(5):e45-66. PubMed ID: 26813745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.